Immunotherapy using redirected allogeneic cells
US9623049B2 · kind B2 · utility
9Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2012 |
| Grant date | Apr 18, 2017 |
| Priority date | — |
| Expiry date | Dec 12, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.